Cancer Cell:ALL干细胞通过建造新骨髓微环境逃避化疗

2014-06-20 黄辛 中国科学报

上海交通大学医学院细胞分化和凋亡教育部重点实验室的研究人员发现,急性淋巴细胞白血病">白血病干细胞通过建造新的骨髓微环境逃避化疗。相关研究成果近日发表在《癌细胞》上。 据介绍,白血病的治疗主要依靠化疗,但化疗难以清除骨髓中的白血病干细胞,导致白血病容易复发。因此,回答化疗开始后骨髓中到底发生了什么?白血病干细胞如何逃避化疗等科学问题对研究治疗策略非常重要。 研究人员先将人急性淋巴细胞白血

上海交通大学医学院细胞分化和凋亡教育部重点实验室的研究人员发现,急性淋巴细胞白血病">白血病干细胞通过建造新的骨髓微环境逃避化疗。相关研究成果近日发表在《癌细胞》上。

据介绍,白血病的治疗主要依靠化疗,但化疗难以清除骨髓中的白血病干细胞,导致白血病容易复发。因此,回答化疗开始后骨髓中到底发生了什么?白血病干细胞如何逃避化疗等科学问题对研究治疗策略非常重要。

研究人员先将人急性淋巴细胞白血病细胞注入小鼠体内,建立白血病小鼠模型,之后给予化疗,用先进的成像技术等进行观察和研究。发现白血病细胞在骨髓中浸润性生长,在实质性破坏正常骨髓微环境后,给予化疗,白血病干细胞会分泌一些细胞因子,招募和改造骨髓间充质干细胞,建立一个临时的“庇护所”,逃避化疗杀伤。正如地震摧毁了房屋,幸存者搭建一个临时帐篷,度过灾难期。

研究者在骨髓里发现并鉴定了这个“临时帐篷”,并将这个新建的“庇护所”称为NSM 微环境。研究者发现,干扰NSM 微环境的形成或保护功能,可以明显提高化疗效果,清除骨髓中残留的白血病干细胞。同时,通过化疗不能缓解或部分缓解的白血病病人样本中,检测到这种微环境的标志物,在完全缓解的白血病人样本中却检测不到。

专家认为,该研究的意义在于:可以通过检测一种标志物来判断病人预后,并靶向干扰其形成或功能,从而提高化疗效果,甚至治愈白血病。同时,该研究也可能应用在其他肿瘤治疗中。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780631, encodeId=99971e806315e, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Apr 22 14:14:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959083, encodeId=d8a019590838a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 10 08:14:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868840, encodeId=b8571868840e2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 11 21:14:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328857, encodeId=ce83132885ea3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511913, encodeId=28201511913a7, content=<a href='/topic/show?id=85631019e1ef' target=_blank style='color:#2F92EE;'>#骨髓微环境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101971, encryptionId=85631019e1ef, topicName=骨髓微环境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6d10409721, createdName=12498561m35(暂无昵称), createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780631, encodeId=99971e806315e, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Apr 22 14:14:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959083, encodeId=d8a019590838a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 10 08:14:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868840, encodeId=b8571868840e2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 11 21:14:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328857, encodeId=ce83132885ea3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511913, encodeId=28201511913a7, content=<a href='/topic/show?id=85631019e1ef' target=_blank style='color:#2F92EE;'>#骨髓微环境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101971, encryptionId=85631019e1ef, topicName=骨髓微环境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6d10409721, createdName=12498561m35(暂无昵称), createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=)]
    2015-02-10 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780631, encodeId=99971e806315e, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Apr 22 14:14:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959083, encodeId=d8a019590838a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 10 08:14:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868840, encodeId=b8571868840e2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 11 21:14:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328857, encodeId=ce83132885ea3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511913, encodeId=28201511913a7, content=<a href='/topic/show?id=85631019e1ef' target=_blank style='color:#2F92EE;'>#骨髓微环境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101971, encryptionId=85631019e1ef, topicName=骨髓微环境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6d10409721, createdName=12498561m35(暂无昵称), createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780631, encodeId=99971e806315e, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Apr 22 14:14:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959083, encodeId=d8a019590838a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 10 08:14:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868840, encodeId=b8571868840e2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 11 21:14:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328857, encodeId=ce83132885ea3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511913, encodeId=28201511913a7, content=<a href='/topic/show?id=85631019e1ef' target=_blank style='color:#2F92EE;'>#骨髓微环境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101971, encryptionId=85631019e1ef, topicName=骨髓微环境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6d10409721, createdName=12498561m35(暂无昵称), createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=)]
    2014-06-22 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1780631, encodeId=99971e806315e, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Wed Apr 22 14:14:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959083, encodeId=d8a019590838a, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Feb 10 08:14:00 CST 2015, time=2015-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868840, encodeId=b8571868840e2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 11 21:14:00 CST 2015, time=2015-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328857, encodeId=ce83132885ea3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511913, encodeId=28201511913a7, content=<a href='/topic/show?id=85631019e1ef' target=_blank style='color:#2F92EE;'>#骨髓微环境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101971, encryptionId=85631019e1ef, topicName=骨髓微环境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca6d10409721, createdName=12498561m35(暂无昵称), createdTime=Sun Jun 22 00:14:00 CST 2014, time=2014-06-22, status=1, ipAttribution=)]

相关资讯

Leukemia:慢性淋巴细胞性白血病患者的潜在新疗法

最近,随着一项新治疗策略的发展,慢性淋巴细胞性白血病(CLL)患者的长期生存时间有望得以增加。由澳大利亚莫纳什大学免疫学系教授Fabienne Mackay和博士研究生Damien Saulep-Easton带领的一项开拓性研究,最近发表在白血病领域的权威杂志 Leukemia ,解开了CLL从未报道过的一面。 慢性淋巴细胞白血病是一种影响B淋巴细胞系的恶性肿瘤,它的特点是产生大量不成熟的淋

Cancer Cell:白血病干细胞为何难以清除

上海交通大学医学院细胞分化和凋亡教育部重点实验室医学干细胞课题组科研人员新近研究发现,急性淋巴细胞白血病干细胞通过建造新的骨髓微环境(niche),搭建“临时庇护所”以逃避化疗。最新一期《癌细胞》杂志发表了相关研究论文。 化疗难以清除骨髓中的白血病干细胞,因此导致白血病容易复发。因此,回答“化疗开始后骨髓中到底发生了什么”等问题,对发展白血病治疗新策略非常重要。 该课题组成

NEJM:急性早幼粒细胞白血病(APL)砷剂耐药的基因突变机制

近日,北京大学血液病研究所黄晓军课题组研究发现急性早幼粒细胞白血病(APL)砷剂耐药的新机制。该研究结果今日以通讯的形式发表在国际医学顶级杂志 New England Journal of Medicine(新英格兰医学杂志),影响因子51.658。这是北京大学人民医院历史上首次在该杂志上发表文章,具有重要的历史意义。      此项研究在13例砷剂耐药病例中,

Cancer Cell:新研究发现与白血病有关的肿瘤干细胞

英国研究人员及其国际同行15日报告说,他们发现了与一种白血病有关的肿瘤干细胞。这类细胞是支撑肿瘤细胞生存和扩散的“罪魁祸首”,识别出它们有助于开发出有针对性的治疗药物。 肿瘤干细胞理论认为,在肿瘤及癌症中,总有一小部分细胞像干细胞那样在促使肿瘤细胞增殖、转移。近年来,研究人员曾先后发现了与前列腺癌等癌症有关的肿瘤干细胞。 英国牛津大学的研究人员和瑞典等国同行在美国新一期《癌细胞》杂志上报告说,

ASCO 2014:马军谈复发难治CLL的靶向研究

CLL及部分淋巴瘤的治疗进入非化疗靶向时代题目:在复发或难治慢性淋巴细胞白血病/小淋巴细胞性淋巴瘤中ibrutinib和oftumumab的随机对照:RSONATE Ⅲ期试验的结果(Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic le

Nat Genet:唐氏综合症与白血病之间的千丝万缕

尽管医生们早就知道,唐氏综合症患者在儿童期间罹患急性淋巴细胞白血病(ALL)的风险更高,但是他们一直不能解释其中的原因。目前,美国Dana-Farber癌症研究所的一个研究小组发现了这两种疾病之间的联系。 在2014年4月20日 Nature Genetics 杂志发表的一项研究中,研究人员追踪了将唐氏综合症染色体异常与ALL中发生的严重细胞破坏联系起来的一连串遗传事件。他们的研究结果不仅与